Start the right treatment sooner
ASPYRE®-Lung provides answers in days not weeks
With more than 25 approved targeted therapies, there is renewed hope for patients with lung cancer.
A prerequisite for prescribing targeted therapy is an analysis of your DNA to determine if you have a biomarker that would respond to such treatment.
Unfortunately, biomarker testing with current technologies can take weeks following diagnosis to obtain test results, often leaving physicians with no choice but to start their patients on systemic, toxic chemotherapies.
ASPYRE-Lung addresses this issue by providing comprehensive biomarker test results within days of diagnosis, providing your physician with the information needed to select the best treatment option that is right for you.
Fast, comprehensive & useful biomarker information
Rapid time to treatment
ASPYRE-Lung is a new biomarker test that reduces the time required to obtain test results, accelerating the start of your therapy from weeks to days.
Existing biomarker tests are costly, often requiring prior authorization from insurance providers before starting therapy. The cost of ASPYRE-Lung is a fraction of the cost of current comprehensive tests.
ASPYRE-Lung tests for all guideline recommended biomarkers that correlate with lung cancer targeted therapies, providing your physician optimal treatment selection opportunities.
We're here for you
Biofidelity believes that every patient deserves the best treatment options. Contact us for more details or call our customer service department at +1 (919) 659-3285 to speak with a customer service representative.
Frequently asked questions
What can I learn from an ASPYRE-Lung test result?
ASPYRE-Lung is a molecular diagnostic test that identifies biomarkers within cancer cells to identify mutations which may provide potential options for you and your doctor to consider in your treatment:
- Therapies you may be eligible for: We identify FDA-approved targeted therapies or immunotherapies that may help you based on the mutations and biomarkers found in your cancer. These therapies have been approved for non-small cell lung cancer (NSCLC).
- Actionable information: ASPYRE-Lung has been thoughtfully designed exclusively for NSCLC patients. The good news is that there are now over 25 targeted therapies available for patients with lung cancer. The ASPYRE-Lung panel includes only those genes that have direct correlation with NSCLC targeted therapies. This simplifies and speeds up the treatment decision process.
How long will it take to receive my test result?
What types of samples can be sent in for the ASPYRE-Lung test?
When should I get an ASPYRE-Lung test if I have been diagnosed with lung cancer?
Does insurance cover my ASPYRE-Lung genomic test?
What is the process for sending a sample to Biofidelity?
What are some reasons why I may not be able to get results after my sample is sent in?
After we receive your sample in our lab, we go through a series of detailed checks to make sure we can return results to your doctor. For tissue samples, we check that there is enough tumor material and tumor DNA in the sample. For all tests, we have additional quality checks before we can issue results.
If we are not able to get results, we will let your doctor know so that a different sample can be sent in. For a tissue test, this could be a different tissue sample. We are committed to working with you and your doctor to find the best chance for getting results to help guide your care.
Is there a charge if results cannot be obtained?
Will I get a copy of my report?
How is my information used?
Your health information may be used and disclosed for treatment, payment, healthcare operations, and other purposes permitted or required by law. Biofidelity may also use your health information to create and use “de-identified” datasets and provide these datasets to biopharma partners, academic researchers, and other third parties to help identify new and better treatments and to advance our understanding of how cancer treatments work. De-identified datasets means that information that could be used to identify a specific individual is removed.
Your de-identified information may be aggregated with thousands of other patients’ de-identified information to generate insights essential to accelerating new discoveries in cancer treatment and ultimately enabling better patient care. However, Biofidelity respects the individual rights of its patients, including a right to opt out of disclosure of their de-identified information to third parties for future research purposes. Any de-identified information already included in a dataset created prior to your opt-out will not be impacted. If you would like to opt out, please contact email@example.com.